X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tryptamine
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: CaaMTech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration December 09, 2020
Details:
The renewal and expansion of this collaboration recognizes the success of Associate Professor of Chemistry & Biochemistry Dr. David R. Manke and his associated team of researchers in the synthesis and crystallography of novel tryptamines.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Neutralizing antibodies
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Distributed Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 03, 2020
Details:
Under the terms of this partnership, Distributed Bio will use its SuperHuman2.0 Antibody Discovery platform to identify lead antibodies for Mediar programs.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KCC2
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Kerry Murphy
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing May 28, 2020
Details:
The funds will enable AXONIS to conduct pre-clinical studies on its novel technology that reactivates spared neural tissue at the spinal cord injury site through upmodulation of the KCC2 protein activity.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
